NCT05764993View on ClinicalTrials.gov

Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

December 30, 2025

Conditions
COPD Exacerbation Acute
Interventions
BIOLOGICAL

CUVITRU - Ig subcutaneous human 20%

Subcutaneous Immunoglobin Replacement Therapy, SCigR

OTHER

Standard Medical Therapy

Standard Medical Therapy

Trial Locations (3)

14607

RECRUITING

Rochester Regional Health Ctr for Clinical Research - Alexander Park, Rochester

14625

RECRUITING

Rochester Regional Health - Ctr for Clinical Research - Linden Oaks, Rochester

14626

RECRUITING

Rochester Regional Health - Ctr for Clinical Research - Greece, Rochester

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Rochester General Hospital

OTHER

NCT05764993 - Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention | Biotech Hunter | Biotech Hunter